Eliquis Market
Eliquis Market Size, Share, Competitive Landscape and Trend Analysis Report By Indication, Distribution Channel, and Form: Global Opportunity and Industry Forecast (2024-2030)
Report ID:
1073
Industry:
Healthcare
Published on:
Oct 2025
The Global Eliquis Market had a value of USD 21.74 billion in 2024 and expected it to hit USD 27.83 billion by 2030, with a CAGR of 4.2% through the forecast period.
Eliquis Market Overview
The Eliquis is related to an oral anticoagulant that helps prevent and treat clots in the bloodstream. Eliquis is mainly used to reduce the risk of stroke in patients diagnosed with atrial fibrillation (AF) and can also be used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). Eliquis has gained considerable acceptance in both developed and developing healthcare markets, comprising its lower bleeding risk compared to other anticoagulants in pre-approval, availability list. By 2024, the market had strong demand from patients on extended treatment regimens, particularly in settings with higher prevalence of cardiovascular disease.
The Eliquis Market had developed steadily as healthcare systems are placing their emphasis on preventive treatment for thromboembolic disorders. Prescription volumes had increased alongside atrial fibrillation diagnoses, which now impact over 38M individuals each year globally. Clinical guidelines across regions continue to support Eliquis as a first-line treatment option, thereby aiding physician and patient acceptance, and ongoing positive growth in production, with more than 2 billion doses dispensed in calendar year 2022 across the hospital and retail pharmacy channels. Access both offline and online has supported the growth of the market. With continued support of anticoagulant therapeutics by government and pharmacy benefit managers/public and private insurers, Eliquis will be a mainstay for reducing complications associated with cardiovascular disease.
The report by Jadhavar Business Intelligence Pvt. Ltd. delivers a comprehensive analysis of the Eliquis Market, covering global, regional, and country-level insights from 2024 to 2030. It includes an overview of market definitions, assumptions, and scope, along with detailed market size, share, and segment analysis by Indication, Distribution Channel and Form. The report provides in-depth market dynamics, trends, drivers, challenges, and opportunities, supported by analytical tools such as PORTER’s Five Forces, PESTLE, technology roadmaps, value chain mapping, and regulatory landscape assessments. Regional deep-dives cover North America, Europe, Asia Pacific, Middle East & Africa, and South America, with country-level forecasts. The competitive landscape section benchmarks leading players, profiles key companies, and analyses strategic developments. The report concludes with strategic recommendations, market opportunities, and key takeaways to guide business decision-making.
Eliquis Market Dynamic’s
The Eliquis Market is driven by the increasing incidence of cardiovascular and thromboembolic-related diseases. In 2023, over 38 million individuals globally were estimated to be living with atrial fibrillation, with numbers expected to reach 60 million by 2030. Eliquis has become a commonly used medication for prevention of stroke in patients with atrial fibrillation, along with data showing a 26% lower chance of major bleeding events compared to warfarin. Increased awareness from health care providers, supportive clinical guidelines, and greater insurance coverage led to increased volume of prescriptions. The market appears to have sustained strong demand momentum with more than 180 million prescriptions filled globally in 2024.
Although the Eliquis Market has grown constantly, some constraining factors exist. High treatment costs represent a significant restraint for access to the drug as monthly therapy costs can exceed $500 in some geographies, particularly for uninsured and lower income patients. Patent protection has helped uphold strong branded sales, but has also restrained affordability in many areas. Complexities in supply chain and dependence on regulatory approval also present challenges for consistent availability in emerging markets. Lack of awareness in underdeveloped healthcare systems and patient concerns about long-term anticoagulant use also act as constraining factors.
The Eliquis Market presents considerable potential in emerging markets and digital health platforms. Cardiovascular disease is responsible for 17.9 million deaths globally each year. In 2023, online pharmacies exhibited a 22% growth in Eliquis sales year-on-year, suggesting digital health platforms will be a key driver for future growth. The potential for opportunities in the Eliquis Market is amplified by the growth into new indications and ongoing clinical trials. The Eliquis Market encounters some challenges the patent expirations in several regions are expected to occur by 2026, and the availability of generic drugs at lower pricing pressure will exist for the branded Eliquis. This is anticipated to limit existing company revenue even with a net increase in drug availability to patients.
Eliquis Market Segment Analysis
The Eliquis Market segmented into by Indication, Distribution Channel and Form.
By Indication
Based on Indication, The Eliquis Market is segmented into Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Post-Operative Venous Thromboembolism (VTE) Prophylaxis and Others. The atrial fibrillation (AF) segment led the Eliquis Market, gathering 41% of the total market share in 2024. This dominance is as a result of the increasing incidence of AF statistics globally, with more than 5 million new cases diagnosed each year. For stroke prevention in AF patients, physicians often prefer Eliquis because it has a lower risk of bleeding compared to older therapies. Also, it is supported by clinical data and guidelines to increase its utilization in this segment.
By Distribution Channel
Based on Distribution Channel, The Eliquis market is segmented by hospital pharmacies, retail pharmacies, and online pharmacies. For instance, in 2024, the hospital pharmacy segment dominated the Eliquis Market with 46% of the total market share. Hospitals remain the main starting point for the initiation of anticoagulation therapies, particularly in patients with newly diagnosed DVT and PE. The need for monitoring patients closely, some of the largest hospital systems engaged in bulk purchasing, and the preference from physicians to have medicines provided through a hospital pharmacy to manage adherence and dosing during early therapy all led to the dominance of this channel.
Eliquis Market Region Analysis
In 2024, the North America region continued to dominate the Eliquis Market, accounting for 52% of the global market. This regional dominance in the Eliquis market is as a result of a high volume of cardiovascular disease, robust insurance coverage, and clinical guidelines that recommend Eliquis as a choice of therapy. Prescription data notes that the United States alone had over 110 million prescriptions for Eliquis in 2024. The North America region also sustained strong market share support from an established healthcare infrastructure, patient education efforts, and sustained adoption rates by providers. Strong research collaboration investments further improved the visibility of Eliquis in the region.
In 2024, the Europe region held a significant share of the Eliquis Market as a result of a growing acceptance for clinical use of governmental healthcare plans. Germany, France, and the United Kingdom recorded high prescription volumes, with more than 45 million prescriptions written altogether in the Europe region. The use of Eliquis for atrial fibrillation and venous thromboembolism is consistently recommended in European guidelines, which helps foster physician comfort with the drug. Additionally, robust reimbursement by national healthcare systems has also afforded patients easier access to prescription medications.
Eliquis Market Competitive Analysis
The Eliquis Market is dominated by Bristol-Myers Squibb and Pfizer, the two companies that share a co-marketing agreement globally. Their marketing strategies involve running large clinical studies or trials; engaging in ongoing outreach to physicians and fostering strong relationships with medical systems, pharmacy groups. The companies invest significantly in systematic, evidence-based efforts to raise awareness of Eliquis' safety and efficacy compared to older anticoagulants among two leading groups: physicians and patients. Growth in digital delivery channels and patient-support programs has also been a significant contributor to sustaining the growth of prescriptions during the Eliquis market's launch stage. Generics from competitors are expected to enter the market, yet Eliquis should be able to maintain its market trends with its strong brand presence, extensive clinical evidence base, and educated physicians.
Report Summary
The Eliquis Market has established itself as a leading therapeutic area in anticoagulation therapy. Rising cardiovascular disease prevalence, particularly atrial fibrillation, continues to drive demand. Hospital pharmacies remain the primary distribution channel, while North America leads in global adoption. Recent developments highlight stronger clinical evidence, regulatory approvals, and growing digital distribution platforms. With upcoming challenges from generic entry, companies are focusing on strengthening brand value, patient support programs, and expanding into underpenetrated regions. Overall, the market maintains strong momentum as Eliquis remains central to modern anticoagulation therapy.
Eliquis Market Scope:
Key Players –
Mylan NV
Sanofi
GSK plc
Novartis AG
AstraZeneca
Johnson & Johnson Private Limited
Bristol-Myers Squibb Company
Bayer AG
Sanofi S.A.
Boehringer Ingelheim GmbH
AstraZeneca PLC
Roche Holding AG
Frequently Ask Questions –
1) What is Eliquis Market?
Ans - The Eliquis Market refers to the global industry for Eliquis (apixaban), an anticoagulant used to treat and prevent blood clots.
2) Which indication leads the Eliquis Market?
Ans - In 2024, atrial fibrillation led the Eliquis Market, accounting for the largest share due to widespread physician preference for stroke prevention.
3) Why is online distribution important in the Eliquis Market?
Ans - The Market benefits from online channels offering convenience and personalization, accounting for over half of sales.
4) Which region dominates the Eliquis Market?
Ans - North America dominates the Eliquis Market with over half of the global share, supported by high prescription volumes and advanced healthcare systems.
5) What drives the Eliquis Market?
Ans - The Eliquis Market is driven by the growing number of atrial fibrillation and thromboembolic cases worldwide, leading to strong prescription demand.